AA
RAPP

AlphaCentric Advisors’s Rapport Therapeutics RAPP Stock Holding History

AlphaCentric Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Buy
6,531
+93
+1% +$3.42K 0.23% 137
2026
Q1 		$201K Buy
6,438
+408
+7% +$11.5K 0.2% 142
2025
Q4 		$183K Buy
+6,030
New +$167K 0.18% 153

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

AlphaCentric Advisors's RAPP Position: Q2 2026 in Review

AlphaCentric Advisors increased its Rapport Therapeutics (RAPP) stake by 1.4% in Q2 2026, buying an estimated $3.42K and bringing the position to 6,531 shares worth $272K. The position accounts for 0.23% of the portfolio, ranked #137.

AlphaCentric Advisors first reported a position in RAPP in Q4 2025 and has held it in 3 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • AlphaCentric Advisors held 6,531 shares of Rapport Therapeutics worth $272K as of Q2 2026.
  • AlphaCentric Advisors bought 93 Rapport Therapeutics shares in Q2 2026, an estimated $3.42K.
  • Rapport Therapeutics made up 0.23% of AlphaCentric Advisors's portfolio in Q2 2026, its #137 holding.
  • AlphaCentric Advisors first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.